LifeSci Acquisition II Corp.

LifeSci Acquisition II Corp.

LifeSci Acquisition II Corp. emerged as a special purpose acquisition company tied to the ecosystem of LifeSci Capital, a New York-based investment bank specializing in healthcare. Its predecessor, LifeSci Acquisition Corp., completed a merger with Vincera Pharma in 2020, taking the oncology-focused biotech public. The blank-check structure draws on the sponsor group's sector-specific advisory network, assembled across offices in San Diego, Palo Alto, and New York, to identify acquisition targets in biotechnology and pharmaceuticals. No public filing confirms the precise management slate for the second vehicle, but prior iterations were led by Andrew McDonald, a co-founder of LifeSci Capital, and affiliates of the advisory firm. The SPAC pursues a negotiated acquisition rather than a blind pool bet: proceeds from the IPO sit in trust while the sponsor scouts a private biotech company with a defined value proposition. Confirmed target parameters from the original S-1 registration prioritize drug development companies with lead assets entering or advancing through clinical trials, ideally with a near-term inflection point anticipated in the subsequent 12 to 24 months. Geographic preferences disclosed in offering documents center on the United States and Europe. The structure does not limit itself by therapeutic area, though the sponsor's prior success with Vincera Pharma hints at oncology familiarity. The vehicle's $75 million trust (per SEC filings, 2020) did not set a floor on target valuation, but the SPAC math suggests a post-merger equity value roughly two to three times the cash in trust after accounting for additional PIPE financing. LifeSci Capital operated a network that included advisory staff in Abu Dhabi and a UK office in Poole, though the SPAC's team size remained lean — typical for a blank-check issuer that relies on the parent bank's personnel. No dedicated investment team numbers are publicly broken out. The adjacent relationships include the parent broker-dealer, which earned fees from follow-on offerings and at-the-market programs for public biotech companies, plus the corporate access platform connecting institutional investors with biotech management teams at conferences. In December 2021, LifeSci Acquisition II Corp. announced a definitive merger agreement with Science 37 Holdings, a decentralized clinical trial technology company, valuing the combined entity at approximately $1 billion (per the firm's press release, December 2021). The transaction closed in October 2021, moving the firm's operational profile from a cash-shell to an operating public company. The structural differentiator is the sponsor's deep, single-industry expertise: rather than a generalist SPAC backing a management team with broad credentials, LifeSci Acquisition vehicles are underwritten by domain specialists whose investment banking franchise already screens hundreds of private biotech companies each year. That sourcing model filters for quality via repeated advisory interactions, not a formal proprietary database, making the SPAC's pipeline a byproduct of ongoing banking mandates. The governance design placed founder affiliates on both sides of the deal — a configuration that drew scrutiny in post-de-SPAC analyst coverage but reflected the sponsor's insistence on alignment with operating partners.